Aclaris Therapeutics (NASDAQ:ACRS) insider Neal Walker purchased 10,000 shares of the company’s stock in a transaction on Thursday, April 5th. The shares were purchased at an average cost of $16.75 per share, with a total value of $167,500.00. Following the purchase, the insider now owns 897,184 shares of the company’s stock, valued at $15,027,832. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Shares of NASDAQ ACRS traded down $0.04 during midday trading on Monday, reaching $16.42. The company had a trading volume of 27,690 shares, compared to its average volume of 317,454. Aclaris Therapeutics has a one year low of $16.01 and a one year high of $33.10. The firm has a market cap of $508.64, a PE ratio of -6.58 and a beta of 1.63.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.10. The company had revenue of $1.00 million during the quarter, compared to the consensus estimate of $0.80 million. sell-side analysts anticipate that Aclaris Therapeutics will post -4.27 earnings per share for the current year.
Several equities research analysts have issued reports on the company. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the stock a “buy” rating in a research note on Monday, January 8th. Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Guggenheim assumed coverage on Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 price target for the company. Finally, Leerink Swann dropped their price target on Aclaris Therapeutics from $56.00 to $54.00 and set an “outperform” rating for the company in a research note on Tuesday, March 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. Aclaris Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $43.50.
TRADEMARK VIOLATION WARNING: This story was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3343476/aclaris-therapeutics-acrs-insider-neal-walker-purchases-10000-shares.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.